A Randomized, Double-Blind, Multicenter Study of Adefovir Dipivoxil in Treating Patients with HBeAg-positive Chronic Hepatitis B

ZHAO Hong,SI Chong-wen,ZHANG Yue-xin,CHEN Xin-yue,WANG Lei,TANG Xiao-ping,LEI Chun-liang

DOI: https://doi.org/10.3760/j.issn:1000-6680.2007.02.009

2007-01-01

Abstract:Objective To evaluate the efficacy and safety of adefovir dipivoxil(ADV)in treating patients with hepatitis B e antigen(HBeAg)positive chronic hepatitis B.Methods In this randomized,double blind,placebo-controlled,multicenter trial,210 eligible patients with HBeAg positive chronic hepatitis B were recruited and randomized(randomization ratio was 2:1)receiving ADV 10 mg/d for 48 weeks(ADV+ADV group,n=142)or placebo for 24 weeks followed by ADV 10 mg/d for 24 weeks(PLB+ADV group,n=68).The primary endpoint was virological response. The secondary endpoint was serologic response(HBeAg loss rate and HBeAg seroconversion rate) and alanine aminotransferase normalization rate.Results After 24 weeks therapy,mean reduction of hepatitis B virus(HBV)DNA level comparing with that of baseline was 3.12 log_(10)copy/mL in ADV +ADV group while it was 0.95 log_(10)copy/mL in PLB+ADV group.The percentages of patients with HBV DNA clearance(HBV DNA level3 log_(10)eopy/mL),HBV DNA inhibition(HBV DNA level5 log_(10)copy/mL)and HBV DNA decrease(the reduction≥2 log_(10)copy/mL comparing with the baseline)in ADV+ADV group were significantly higher than those in PLB+ADV group (26.1%,90.8%,85.9%vs 1.5%,29.4%,19.1%,respectively,P=0.000).The alanine amin- otransferase normalization rate in ADV+ADV group was significantly greater than that in PLB+ ADV group(54.2% vs 5.9%,P=0.000).HBeAg loss rate and HBeAg seroconversion rate in ADV+ADV group were slightly higher than those in PLB+ADV group(12.9% and 7.0% vs 5.9% and 4.4 %,respectively),hut the differences were not statistically significant.In both groups,more patients achieved virological response,serologic response and alanine aminotransferase normalization after continuous 24 weeks therapy.The overall safety profile of ADV was similar to that of placebo. rtN236T and(or)rtA181V mutations were not detected during 48 weeks therapy.Conclusions ADV is an effective and well-tolerated treatment for patients with HBeAg positive chronic hepatitis B.